Compare SFBC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | ONCY |
|---|---|---|
| Founded | 1953 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 94.0M |
| IPO Year | N/A | 1999 |
| Metric | SFBC | ONCY |
|---|---|---|
| Price | $43.57 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.7K | ★ 513.5K |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ 74.62 | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $38,709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.28 | ★ N/A |
| Revenue Growth | ★ 10.38 | N/A |
| 52 Week Low | $42.75 | $0.33 |
| 52 Week High | $55.00 | $1.51 |
| Indicator | SFBC | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 49.75 |
| Support Level | $43.11 | $0.86 |
| Resistance Level | $43.70 | $1.00 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 32.73 | 59.32 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.